Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.06, Zacks reports. During the same period in the prior year, the firm posted ($0.24) earnings per share.
Acurx Pharmaceuticals Trading Down 1.1 %
NASDAQ ACXP traded down $0.02 during trading hours on Wednesday, reaching $1.83. 10,195 shares of the company’s stock were exchanged, compared to its average volume of 90,404. The firm has a fifty day moving average of $1.97 and a 200-day moving average of $2.15. Acurx Pharmaceuticals has a one year low of $1.52 and a one year high of $5.28. The stock has a market cap of $29.74 million, a PE ratio of -1.58 and a beta of -1.73.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Acurx Pharmaceuticals in a research report on Monday, August 12th.
About Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
See Also
- Five stocks we like better than Acurx Pharmaceuticals
- Consumer Staples Stocks, Explained
- Rocket Lab is the Right Stock for the Right Time
- Russell 2000 Index, How Investors Use it For Profitable Trading
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
